Why the study?
Control of several cardiovascular risk factors remains suboptimal in many CAD patients with a high rate of recurrent events, underlying the need for new prevention strategies.
Does the GAPS-I strategy reduce major adverse cardiovascular events and mortality in patients with coronary artery disease and high residual cardiovascular risk?
Does the GAPS-I strategy reduce major adverse cardiovascular events and mortality in patients with coronary artery disease and high residual cardiovascular risk?
The GAPS-I strategy provides a structured, individualized approach using novel pharmacological agents to address high residual cardiovascular risk in patients with coronary artery disease.
Answers are grounded in this paper and cite their sources.
May support GAPS-I in high-risk CAD; leaves open need for RCTs before practice change.
The continuous progress in cardiovascular risk prevention strategies has led to an impressive reduction in mortality and recurrent ischemic events in patients with coronary artery disease (CAD). However, the control of several cardiovascular risk factors remains suboptimal in many CAD patients, with a high rate of recurrent events, underlying the need for more new prevention strategies. The GAPS-I (glucagon-like peptide 1 analogues, antithrombotic agents, proprotein convertase subtilisin/kexin type 9 inhibitors, sodium glucose cotransporter type 2 inhibitors and immunomodulators) strategy offers a promising potential in patients with a high-residual cardiovascular risk, who are frequently encountered in daily practice, by offering an individualized and structured approach to addressing their individual risk factors. The current review summarizes the evidence to date on each of its components, with respect to clinical outcomes and economic feasibility. The current evidence points to an efficacy of GAPS-I in reducing major adverse cardiovascular events and mortality, without a compromise on safety, albeit with the need for longer follow-up data.
No takes yet. Share an insight, caveat, or question.
Sabouret et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: